Dr Catherine Bladen, Chief Operations Officer
Catherine has more than 15 years’ experience in biochemistry research (specifically protein identification, purification and characterization) both in the UK and in the USA. She completed her PhD in 2001 in the Cancer Research Unit at Newcastle University, studying novel proteins involved in p53 independent cancer pathways. From there, Catherine spent 6 years at the Medical College of Georgia (USA) identifying proteins involved in double stranded DNA repair as a consequence of medical radiation exposure (radiotherapy). Catherine then spent 7 years at Leeds University researching the role of DNA repair and oxidative stress in Osteoarthritis. A further two years were then spent at Newcastle University leading a large, multi-national research project identifying mutations leading to Duchenne Muscular Dystrophy in an effort to understand how mutation status and clinical outcomes were connected. Catherine joined Absolute Antibody in 2015 and leads our research and production teams.
Dr Michael Fiebig, Chief Scientific Officer
Michael studied Biochemistry before obtaining his doctoral degree at the Sir William Dunn School of Pathology, University of Oxford. With a background in both wet-lab and bioinformatic methods, Michael is always keen to explore new antibody licensing, product development and service opportunities to help customers and business partners harness the benefits of recombinant antibody technology. With in-depth knowledge of our products, Michael is the first point of call for our catalog customers and distributors.
Dr Jennifer Rossi, Vice President Americas
In her work roles, Jen enjoys merging her scientific background with business planning and strategy. With a BS/MS from Ohio University and a PhD from Brown University, Jen has held roles at Cohesive Technologies (now part of ThermoFisher), Qiagen, BioTrove (acquired by Life Technologies) and Biocius (now part of Agilent). Jen is President of a non-profit organization, the CMA, which supports 1,500 families in her downtown Boston neighborhood of Charlestown. She also supports several canine rescue groups, enjoys being a mentor and is Trustee of the USS Constitution Museum.
Neil Briggs-Evison, Global Financial Controller
Neil started his career in the treasury department at GCHQ in Cheltenham, UK. After working in a number of NHS Trust treasury departments and independent SME’s, he became the Finance Director of the Bottle Green Drinks Company. After a successful VC buyout, Neil found himself in Asia working in accounts, HR and administration for a number of charities across Thailand and Cambodia. In 2015, Neil returned to his roots in the North East of England and joined the then small team at Absolute Antibody. Three years later he heads up the company accounts, shipping exports and imports, general administration and HR team.
Dr Nicholas Hutchings, Chief Technology Officer
Nicholas is an entrepreneur with a background in immunology and proteomics, whose first startup Everest Biotech Ltd made 5000 traditional antibodies for the research market. He studied Biochemistry at the University of Oxford followed by a doctorate at the Sir William Dunn School of Pathology, supervised by Prof Neil Barclay.
Dr Ian Wilkinson
Ian has a scientific background firmly in the engineering and development of therapeutic antibodies. During a UCB-Celltech sponsored PhD at the University of Leicester, Ian solved the first NMR structure of a human antibody fragment (scFv). From there he moved to MedImmune, the biologics arm of AstraZeneca. He worked on a number of antibody and non-antibody early stage therapeutic research projects covering technology validation, drug discovery and optimization. Ian has been with Absolute Antibody since its founding and developed many of the processes that underpin the company’s recombinant antibody services. With a proven track-record of work on the structure-function relationship of various antibody formats, from full-length to scFv, Ian is eager to apply his expertise to even the most challenging antibody engineering projects.